Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
100 participants
INTERVENTIONAL
2020-05-31
2020-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ivermectin In Treatment of COVID 19 Patients
NCT04425707
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
NCT04351347
Prophylactic Ivermectin in COVID-19 Contacts
NCT04422561
Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
NCT04668469
Inhaled Ivermectin and COVID-19
NCT04681053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ivermectin group
group that will receive ivermectin plus standard of care ttt
Ivermectin
3 successive days ttt of ivermectin started within 48 hours of symptoms
Control group
group that will receive standard of care ttt
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivermectin
3 successive days ttt of ivermectin started within 48 hours of symptoms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Waheed Shouman
professor of chest diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Waheed Shouman
Zagazig, Sharqia Province, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZU-IRB#6151/31-5-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.